This inventor holds 3 USPTO granted patents. Top assignee: Bayer Aktiengesellschaft. Active years: 1992-1993.
Company Filing History:
Years Active: 1992-1993
Title: Jorgen Weinschenck: Innovator in Concentration Processes
Introduction
Jorgen Weinschenck is a notable inventor based in Krefeld, Germany. He has made significant contributions to the field of concentration processes, particularly in solutions containing salts and polymers. With a total of 3 patents to his name, Weinschenck's work has had a considerable impact on industrial applications.
Latest Patents
Weinschenck's latest patents include innovative methods for concentrating solutions. One of his patents describes a continuous process for concentrating solutions containing salts. This method improves yield and economics by utilizing a flow tube with a steady curvature, ensuring that at least 90% by weight of the vaporizable components are evaporated off at specific temperature gradients. Another patent focuses on concentrating polymer solutions to a desired specification level of residual solvents. This process prevents encrustations and enhances yield and purity by heating the product under pressure and expanding it through a restrictor element.
Career Highlights
Jorgen Weinschenck is associated with Bayer Aktiengesellschaft, a leading global company in the pharmaceutical and life sciences sector. His work at Bayer has allowed him to develop and refine his innovative concentration processes, contributing to the company's advancements in technology and efficiency.
Collaborations
Weinschenck collaborates with Clemens Casper, a fellow innovator in the field. Their partnership has fostered the development of new techniques and solutions that enhance the effectiveness of concentration processes.
Conclusion
Jorgen Weinschenck's contributions to the field of concentration processes demonstrate his commitment to innovation and excellence. His patents reflect a deep understanding of the complexities involved in concentrating solutions, making him a valuable asset to Bayer Aktiengesellschaft and the broader scientific community.